Anti-angiogenic agents in metastatic colorectal cancer

Table 2 Phase III trials using bevacizumab in the second-line setting

Ref.	Regimen	PFS (mo)	P value	OS (mo)	P value
Giantonio et al[41]; (E3200)	FOLFOX4 ± bevacizumab	7.3 vs 4.7	< 0.0001	12.9 vs 10.8	0.0011
Bennouna et al[45]; (ML18147)	Chemotherapy ± bevacizumab	5.7 vs 4.1	< 0.0001	11.2 vs 9.8	0.0062
Masi et al[46]; (BEBYP)	Chemotherapy ± bevacizumab	6.8 vs 5.0	0.010	14.1 vs 15.51	0.0431

¹The lower median OS in the bevacizumab arm was due to intersection of curves; adjusted HR was 0.77 (stratified log-rank P = 0.043) and favored the bevacizumab arm. PFS: Progression-free survival; OS: Overall survival.